Results 171 to 180 of about 130,637 (269)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr   +15 more
wiley   +1 more source

Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial. [PDF]

open access: yesEur J Heart Fail
Inciardi RM   +15 more
europepmc   +1 more source

Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis

open access: yesESC Heart Failure, EarlyView.
Epicardial adipose tissue (EAT) has been linked to adverse remodelling and outcomes in aortic valve stenosis (AS), yet mechanisms remain unclear. In 137 patients with severe AS undergoing CMR before TAVR, higher EAT (≥46.5 ml/m2) was associated with impaired left atrial (LA) reservoir strain, while ventricular morphology, function and tissue ...
Judith Gronwald   +10 more
wiley   +1 more source

Default mode network connectivity contributes the augment effect stress recovery by natural viewing. [PDF]

open access: yesNeurobiol Stress
Chen Z   +8 more
europepmc   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

open access: yesESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp   +9 more
wiley   +1 more source

Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo‐controlled, crossover trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a major healthcare burden with limited treatment options. Geranylgeranylacetone (GGA) has been shown to improve myocardial compliance and endothelial function in preclinical models.
Soufiane Nassiri   +11 more
wiley   +1 more source

Tissue Engineered Elastic Cartilage-Mimetic Auricular Grafts for Ear Reconstruction

open access: yes
Fisch P   +13 more
europepmc   +1 more source

Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer

open access: yesEuropean Journal of Heart Failure, EarlyView.
Cardiac wasting‐associated cardiomyopathy in cancer patients. E/e', early diastolic filling velocity (E) over mitral annulus early diastolic tissue velocity (e'); GLS, global longitudinal strain; LV, left ventricular; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion.
Markus S. Anker   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy